REG - Venture Life Group - Notice of Annual General Meeting

Venture LifeAnnouncement

05/06/2025 14:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250605:nRSE6658La&default-theme=true

RNS Number : 6658L  Venture Life Group PLC  05 June 2025

5 June 2025

VENTURE LIFE GROUP PLC

("Venture Life", "VLG" or the "Company")

Notice of Annual General Meeting

Venture Life (AIM: VLG), a leader in developing, manufacturing and
commercialising products for the self-care market, announces that notice of
the Annual General Meeting of the Company has today been posted to
shareholders and will be available shortly on the Company's website (the
"AGM").

The Company's AGM will be held at 10.00 a.m. on 30 June 2025 at the offices of
Simmons & Simmons LLP, CityPoint, 1 Ropemaker Street, London, EC2Y 9SS.

The Company announced on 12 May 2025 that it had expected to release its
audited results for the year ended 31 December 2024 on 19 June 2025. Due to
the ongoing workstreams associated with the completion of the divestment of
the CDMO operations and non-core products, it is now anticipated that the
Company will publish the audited results and send the annual report and
accounts to shareholders  (the "2024 Annual Report and Accounts") in late
June 2025.

As the AGM is required to be held on 30 June 2025 at the latest and the 2024
Annual Report and Accounts will not be available to be circulated in
sufficient time for the AGM, the AGM business does not include a resolution to
receive the 2024 Annual Report and Accounts. As a result, the Company's
Directors intend to hold a separate general meeting at a later date for the
shareholders to vote on a resolution to receive  the 2024 Annual Report and
Accounts (the "General Meeting"). The Company will confirm the proposed date
of the General Meeting as soon as practicable, however, it is currently
anticipated that the date will be held in early August.

 

For further information, please contact:

 

 Venture Life Group PLC                                    +44 (0) 1344 578004
 Jerry Randall, Chief Executive Officer

 Daniel Wells, Chief Financial Officer

 Cavendish Capital Markets Limited (Nomad and Broker)      +44 (0) 20 7720 0500
 Stephen Keys / George Lawson (Corporate Finance)

 Michael Johnson (Sales)

About Venture Life (www.venture-life.com (https://www.venture-life.com/) )

Venture Life is an international consumer self-care company focused on
developing, manufacturing and commercialising products for the global
self-care market. With operations in the UK, Italy, The
Netherlands and Sweden, the Group's product portfolio includes Balance Activ
in the area of women's intimate healthcare, Earol® supporting ENT care, Lift
and Glucogel product ranges for energy and glucose management and
hypoglycaemia, the Health and Her product range supporting the hormonal
lifecycle, the UltraDEX and Dentyl oral care product ranges, products for
fungal infections and proctology, and dermo-cosmetics for addressing the signs
of ageing.

The products, which are typically recommended by pharmacists or healthcare
practitioners, are available primarily through pharmacies and grocery
multiples and are sold in over 90 countries worldwide. In the UK and The
Netherlands these are supplied direct by the company to retailers, elsewhere
they are supplied by the Group's international distribution partners.

Through its two Development & Manufacturing operations
in Italy and Sweden, the Group also provides development and manufacturing
services to companies in the medical devices and cosmetic sectors.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAFAMJTMTBMBRA